Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1019-1024

  Manosuthi, Weerawat ^a   Sukasem, Chonlaphat ^b   Lueangniyomkul, Aroon ^a   Mankatitham, Wiroj ^a   Thongyen, Supeda ^a   Nilkamhang, Samruay ^a   Manosuthi, Sukanya ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; RIFAMPICIN; TENOFOVIR;

ACTINOMYCETALES INFECTION; ADULT; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; TUBERCULOSIS;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG INTERACTIONS; ETHAMBUTOL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; ISONIAZID; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRAZINAMIDE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TUBERCULOSIS; YOUNG ADULT;

EID: 84872869312     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02023-12     Document Type: Article

References (30)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
2. Raviglione MC, Snider DE, Jr, Kochi A. 1995. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 273:220-226.
3. Ruxrungtham K, Phanuphak P. 2001. Update on HIV/AIDS in Thailand. J. Med. Assoc. Thai. 84(Suppl 1):S1-S17.
4. Sharma SK, Mohan A, Kadhiravan T. 2005. HIV-TB co-infection: Epidemiology, diagnosis & management. Indian J. Med. Res. 121:550-567.
5. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3:S231-S279.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 15 July 2012.
7. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
8. Breen RA, Swaden L, Ballinger J, Lipman MC. 2006. Tuberculosis and HIV co-infection: A practical therapeutic approach. Drugs 66:2299-2308.
9. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. 2007. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116:496-526.
10. Phillips EJ, Mallal SA. 2008. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr. Opin. Infect. Dis. 21:16-24.
11. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C. 2008. High prevalence of the CYP2B6 516G¡T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64:357-365.
12. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S. 2009. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob. Agents Chemother. 53:863-868.
13. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, Shioda T, Khusmith S. 2010. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res. Ther. 7:8. doi:10.1186/1742-6405-7-8.
14. Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. 2009. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), San Francisco, CA, 2012, poster H-894.
15. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM. 2007. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81:557-566.
16. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237.
17. Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. 2012. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol. 74: 1005-1012.
18. Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H. 2010. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther. Drug Monit. 32:573-578.
19. Guan S, Huang M, Chan E, Chen X, Duan W, Zhou SF. 2006. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur. J. Pharm. Sci. 29:14-21.
20. Manosuthi W, Sungkanuparph S, Tantanathip P, Mankatitham W, Lueangniyomkul A, Thongyen S, Eampokarap B, Uttayamakul S, Suwanvattana P, Kaewsaard S, Ruxrungtham K. 2009. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob. Agents Chemother. 53:4545-4548.
21. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S. 2008. Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir. Ther. 13:675-685.
22. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73:20-30.
23. Friedland G, Khoo S, Jack C, Lalloo U. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:1299-1302.
24. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. 2008. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation. J. Clin. Pharmacol. 48:1032-1040.
25. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Jr, Donahue JP, Kim RB. 2005. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An adult AIDS Clinical Trials Group study. J. Infect. Dis. 192:1931-1942.
26. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, Ingelman-Sundberg M. 2006. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16:191-198.
27. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM. 2005. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15:861-873.
28. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Gunthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A. 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19:300-309.
29. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. 2009. CYP2B6 (c. 516G¡T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67:427-436.
30. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K. 2009. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: The N2R study. Clin. Infect. Dis. 48:1752-1759.